Claims for Patent: 10,654,940

✉ Email this page to a colleague

Summary for Patent: 10,654,940

Title:	Method for treating joint damage
Abstract:	Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
Inventor(s):	Totoritis; Mark (Rancho Santa Fe, CA), Shaw; Timothy Mark (Hertfordshire, GB), Agarwal; Sunil (Corte Madera, CA), Yocum; David (San Mateo, CA), Kelman; Ariella (Hillsborough, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) Biogen Inc. (Cambridge, MA)
Application Number:	16/526,727
Patent Claims:	1. A method for the treatment of joint damage caused by rheumatoid arthritis in a subject, wherein (a) the subject has exhibited an inadequate response to one or more antitumor necrosis factor (TNF) inhibitors; (b) the subject received a prior course of treatment with two 1000 mg intravenous (IV) doses of rituximab given 14 days apart and responded to the prior course of treatment and (c) the treatment comprises administering a further course of treatment with two 1000 mg IV doses of rituximab given 14 days apart and administered at weeks 24 to 40, wherein the subject to whom the further course of treatment is administered has active disease, wherein the method slows or halts progression of structural joint damage for at least about 52 weeks in the subject. 2. The method of claim 1 wherein the further course is administered at about week 24. 3. The method of claim 1 further comprising administering methotrexate (MTX) to the subject. 4. The method of claim 3 further comprising administering corticosteroid to the subject prior to each rituximab administration.

Details for Patent 10,654,940

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,654,940	2039-07-30
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	February 19, 2002	10,654,940	2039-07-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,654,940

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	200804288	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2007059188	⤷ Start Trial
United States of America	2021024643	⤷ Start Trial
United States of America	2019382501	⤷ Start Trial
United States of America	2019270824	⤷ Start Trial
United States of America	2016176974	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.